AU
UK
CA
NZ
IND
US
Lacutamab granted FDA Breakthrough Therapy Designationfor relapsed or refractory Sézary syndrome.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced significant progress in the development of its proprietary antisense oligonucleotide (ASO) drug candidate, HT-KIT. The biopharmaceutical company is focused on creating therapies for allergic and inflammatory diseases, and HT-KIT represents an innovative approach to treating conditions such …
Highlights
Opthea Limited (NASDAQ:OPT), a clinical-stage biopharmaceutical company, has announced the results of its global Phase 3 COAST (Combination OPT-302 with Aflibercept Study) trial, which evaluated the combination therapy of sozinibercept and aflibercept for the treatment of wet age-related macular degeneration (wet AMD). The trial …
Please wait processing your request...